{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:04:33Z","timestamp":1756339473406,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,10,30]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Tumour lysis syndrome (TLS) is a life-threatening complication wherein massive tumour cell lysis results in severe metabolic abnormalities. TLS generally follows chemotherapy of rapidly proliferating haematological malignancies; spontaneous TLS and TLS from treatment of solid tumours are infrequently reported. We present a rare case of TLS following treatment of a large gastrointestinal stromal tumour (GIST) in a 63-\u2009year-old man. Imatinib was started for tumour size reduction prior to surgical intervention and in 5 days the patient developed metabolic derangements consistent with TLS. Imatinib was held and fluids, allopurinol and rasburicase were started. All metabolic abnormalities resolved in 3\u2009days. Imatinib was restarted, and he eventually underwent surgical intervention. This is the second case demonstrating successful reinitiation of imatinib following TLS when treating GIST. We highlight the importance of risk factor assessment and need for pre-emptive therapy to prevent TLS when using tyrosine kinase inhibitor therapy.<\/jats:p>","DOI":"10.1136\/bcr-2018-226647","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:19:47Z","timestamp":1545153587000},"page":"e226647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST"],"prefix":"10.1136","volume":"11","author":[{"given":"Juliann","family":"Ondecker","sequence":"first","affiliation":[{"name":"Med One Hospitalist Internal Medicine, Riverside Methodist Hospital, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geno","family":"Kordic","sequence":"additional","affiliation":[{"name":"Internal Medicine, Riverside Methodist Hospital, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-603X","authenticated-orcid":false,"given":"Kim","family":"Jordan","sequence":"additional","affiliation":[{"name":"Internal Medicine, Riverside Methodist Hospital, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"2025082707470670000_11.1.e226647.1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.medcli.2016.10.040","article-title":"Tumor lysis syndrome in solid tumors: Clinical characteristics and prognosis","volume":"148","author":"Caravaca-Font\u00e1n","year":"2017","journal-title":"Med Clin"},{"key":"2025082707470670000_11.1.e226647.2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4081\/rt.2014.5389","article-title":"Tumor lysis syndrome in solid tumors: an up to date review of the literature","volume":"6","author":"Mirrakhimov","year":"2014","journal-title":"Rare Tumors"},{"key":"2025082707470670000_11.1.e226647.3","first-page":"10","article-title":"Tumor lysis syndrome in a patient with metastatic non-small cell lung cancer: case report and literature review","volume":"4","author":"Myint","year":"2015","journal-title":"Cancer Treat Commun"},{"key":"2025082707470670000_11.1.e226647.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0790"},{"key":"2025082707470670000_11.1.e226647.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2007\/82012","article-title":"Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)","volume":"2007","author":"Pinder","year":"2007","journal-title":"Sarcoma"},{"key":"2025082707470670000_11.1.e226647.6","first-page":"1782","article-title":"Successful re-administration of imatinib without recurrence of tumor lysis syndrome in a patient with peritoneal gastrointestinal stromal tumor","volume":"111","author":"Terada","year":"2014","journal-title":"Japanese J of Gastroenterology"},{"key":"2025082707470670000_11.1.e226647.7","first-page":"20","article-title":"Imatinib Induced Tumor Lysis Syndrome in a Patient with Gastrointestinal Stromal Tumor","volume":"41","author":"Karachiwala","year":"2015","journal-title":"DMJ"},{"key":"2025082707470670000_11.1.e226647.8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.36959\/621\/589","article-title":"Tumor Lysis Syndrome in Gastrointestinal Stromal Tumor Treated with the Oral Tyrosine Kinase Inhibitor Imatinib: A Case Report","volume":"1","author":"Jeng-Nian","year":"2017","journal-title":"J Gastroenterol Res"},{"key":"2025082707470670000_11.1.e226647.9","first-page":"1","article-title":"Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease","volume":"2017","author":"Platoff","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"2025082707470670000_11.1.e226647.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"2025082707470670000_11.1.e226647.11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/TCRM.S1526","article-title":"Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate","volume":"4","author":"Din","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2025082707470670000_11.1.e226647.12","first-page":"110","article-title":"Systemic Treatment for Gastrointestinal Stromal Tumor\u2014A State of Art","volume":"10","author":"Feng","year":"2014","journal-title":"Oncology & Hematology Review"},{"key":"2025082707470670000_11.1.e226647.13","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200001000-00008"},{"key":"2025082707470670000_11.1.e226647.14","doi-asserted-by":"crossref","first-page":"CMO.S4259","DOI":"10.4137\/CMO.S4259","article-title":"Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors","volume":"5","author":"Ksienski","year":"2011","journal-title":"Clin Med Insights Oncol"},{"key":"2025082707470670000_11.1.e226647.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441404"},{"key":"2025082707470670000_11.1.e226647.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-011-0729-7","article-title":"The safety profile of imatinib in CML and GIST: long-term considerations","volume":"86","author":"Thanopoulou","year":"2012","journal-title":"Arch Toxicol"},{"key":"2025082707470670000_11.1.e226647.17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cncr.24683","article-title":"Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate","volume":"116","author":"Trent","year":"2010","journal-title":"Cancer"},{"key":"2025082707470670000_11.1.e226647.18","unstructured":"KDIGO Clinical Practice Guideline for Acute Kidney Injury. https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-AKI-Guideline-English.pdf (Accessed May 2017)."},{"key":"2025082707470670000_11.1.e226647.19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00280-002-0556-x","article-title":"Acute tumor lysis syndrome in solid tumors\u2013a case report and review of the literature","volume":"51","author":"Baeksgaard","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025082707470670000_11.1.e226647.20","first-page":"101","article-title":"Prevention and management of tumor lysis syndrome in adults with malignancy","volume":"4","author":"Sarno","year":"20132013","journal-title":"J Adv Pract Oncol"},{"key":"2025082707470670000_11.1.e226647.21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13403"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bcr-2018-226647","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:47:18Z","timestamp":1756306038000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,11,28]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bcr-2018-226647"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226647","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}